Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Accenture
Daiichi Sankyo
UBS
Boehringer Ingelheim
Fish and Richardson
Cerilliant
Julphar
Queensland Health
Medtronic

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Methods for inhibiting bone loss by treating with aroylbenzothiophenes and estrogen
Abstract:The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
Inventor(s): Black; Larry J. (Indianapolis, IN), Cullinan; George J. (Trafalgar, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Filing Date:Apr 14, 1995
Application Number:08/422,096
Claims:1. A pharmaceutical formulation comprising an effective amount of a compound of formula I ##STR11## wherein X is a bond, CH.sub.2, or CH.sub.2 CH.sub.2 ;

R and R.sup.1, independently, are hydrogen, hydroxyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -acyloxy, C.sub.1 -C.sub.6 -alkoxy-C.sub.2 -C.sub.6 -acyloxy, R.sup.3 -substituted aryloxy, R.sup.3 -substituted aroyloxy, R.sup.4 -substituted carbonyloxy, chloro, or bromo;

R.sup.2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino;

R.sup.3 is C.sub.1 -C.sub.3 -alkyl, C.sub.1-C.sub.3 -alkoxy, hydrogen, or halo; and

R.sup.4 is C.sub.1 -C.sub.6 -alkoxy or aryloxy; or

a pharmaceutically acceptable salt thereof; estrogen and

a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Chinese Patent Office
Baxter
Covington
Federal Trade Commission
Merck
Fish and Richardson
Colorcon
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot